Which is actually sorta surprising given the rollout of third-generation antidepressants during that time.
More consistent with the blue line falling due in part to better treatments. (If they’re significantly better; may well be more widely prescribed anyway.)
Which is actually sorta surprising given the rollout of third-generation antidepressants during that time.
More consistent with the blue line falling due in part to better treatments. (If they’re significantly better; may well be more widely prescribed anyway.)